Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:G16H* AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/237292METHODS OF ASSESSING RISK OF DEVELOPING A SEVERE RESPONSE TO CORONAVIRUS INFECTION
WO 02.12.2021
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
Appl.No PCT/AU2021/050507 Applicant GENETIC TECHNOLOGIES LIMITED Inventor DITE, Gillian Sue
The present disclosure relates to methods and systems for assessing the risk of a human subject developing a severe response to a Coronavirus infection, such as a severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus infection.
2.WO/2021/247682METHODS FOR MITIGATING OR DIMINISHING SPREAD OF PATHOGENIC INFECTIONS
WO 09.12.2021
Int.Class G16H 50/80
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
80for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
Appl.No PCT/US2021/035421 Applicant ROSS, Peter M. Inventor ROSS, Peter M.
The present methods comprise initial administration of a first rapid test, such as rapid antigen test, that has a low likelihood of false positive results and a known likelihood of false negative results, alone or in conjunction with other rapid tests, to identify a first subpopulation of positives, to which an infection mitigation protocol (such as quarantine or the administration of a therapeutic treatment) is administered. Negatives are recorded and provisionally released from further study. A diagnostic test is then administered to this subpopulation, to identify the portion of this first subpopulation that were false positives in the first test. Ideally, a positive result for the diagnostic test is pathognomonic for the infection. Any infection mitigation protocol (such as quarantine) may then be discontinued for those testing negative in the first population and intensified for those testing positive, such as with contact tracing or other protocols, to identify all true positives and those they may have infected within the population.
3.20210290970ILLUMINATION DEVICES FOR INDUCING BIOLOGICAL EFFECTS
US 23.09.2021
Int.Class A61N 5/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
5Radiation therapy
06using light
Appl.No 17162259 Applicant KNOW Bio, LLC Inventor F. Neal Hunter

Illumination devices for impinging light on tissue, for example within a body cavity of a patient, to induce various biological effects are disclosed. Biological effects may include at least one of inactivating and/or inhibiting growth of one or more pathogens, upregulating a local immune response, increasing endogenous stores of nitric oxide, releasing nitric oxide from endogenous stores, and inducing an anti-inflammatory effect. Wavelengths of light are selected based on intended biological effects for one or more of targeted tissue types and targeted pathogens. Light treatments may provide multiple pathogenic biological effects, either with light of a single wavelength or with light having multiple wavelengths. Devices for light treatments are disclosed that provide light doses for inducing biological effects on various targeted pathogens and tissues with increased efficacy and reduced cytotoxicity. Illumination devices may be configured to communicate with networks and/or servers to provide control and/or management of phototherapy treatments.

4.WO/2021/191829ASSAYS FOR DETECTING PATHOGENS
WO 30.09.2021
Int.Class C12Q 1/6869
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6869Methods for sequencing
Appl.No PCT/IB2021/052463 Applicant ANGSTROM BIO, INC. Inventor SANTOS, Carlos F.
Provided herein are compositions and methods for identifying target nucleic acids that are determinants of pathogenic infections. The multiplexed methods provided herein simultaneously detect target proteins such as IgG and IgM immunoglobulins that are indicative of one or more pathogenic infections, from several distinct biological samples. Also provided herein are methods for detecting sequence variants in a nucleic acid sample.
5.WO/2021/236288INTELLIGENT WORKFLOW ANALYSIS FOR TREATING COVID-19 USING EXPOSABLE CLOUD-BASED REGISTRIES
WO 25.11.2021
Int.Class G16H 50/80
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
80for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
Appl.No PCT/US2021/028647 Applicant HOFFMANN-LA ROCHE INC. Inventor MOLERO LEON, Silvia Elena
Disclosed herein are systems, methods, and techniques for building and using a data platform to facilitate intelligent identification of coronavirus disease 2019 (COVID-19) related diagnoses, treatment selection, and interaction tracing. The present disclosure relates to a cloud-based application that generates outputs predictive of a subject's COVID-19 diagnoses and/or suitability for COVID-19 treatments.
6.20210335501SYSTEMS AND METHODS FOR MASS TESTING A POPULATION FOR A CONTAGIOUS INFECTION VIA POOLED SAMPLE TESTING
US 28.10.2021
Int.Class G16H 50/80
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
80for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
Appl.No 17238275 Applicant RANGASWAMY RAJAGOPAL Inventor RANGASWAMY RAJAGOPAL

Disclosed herein are systems and methods for the mass testing of a population for an infection. Pooled sampling may be used to reduce the number of tests needed for effective community surveillance. Individual members may be sorted into pools via a probability of infection to minimize the tests needed to identify positive individuals. The detection limits of testing assays may be used to help determine an appropriate pool size. Taxonomy tables characterizing the solution space of the total tests needed based on different variables may be generated and/or used to make testing decisions. Simulations of mass testing schemes may be used to facilitate testing decisions. Systems may be used to coordinate data and/or automate one or more steps of the testing process. Long-term community surveillance strategies may use prevalence testing, periodic mass testing via sample pooling, and/or periodic single sample testing to contain the spread of a contagion.

7.2020103841A SYSTEM AND A METHOD FOR QUARANTINE EPIDEMIC MODELS
AU 24.12.2020
Int.Class G16H 50/80
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
80for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
Appl.No 2020103841 Applicant Kumar Keshri, Ajit Inventor Kumar Keshri, Ajit
The present disclosure relates to a system and a method for quarantine epidemic models. The disclosed system facilitates three quarantine models of pandemic which accounts the compartments including susceptible population, immigrant population, home isolation population, infectious population, hospital quarantine population, and recovered population. Local and global asymptotic stability is proved for all the three models. Extensive numerical simulations are performed to establish the analytical results with suitable examples. The system discloses that home isolation and quarantine to hospitals are the two-pivot force-control policies under the present situation when no treatment is available for this pandemic.
8.20210307614Systems and methods for detecting infectious pathogens
US 07.10.2021
Int.Class A61B 5/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes; Identification of persons
Appl.No 17195739 Applicant Kaligia Biosciences, LLC Inventor Fazal A Fazlin

Methods and systems are provided for detecting infectious pathogens in a saliva sample by using a Raman spectrometer to obtain Raman spectrum data of the saliva sample. A score is determined based on the Raman spectrum data using a machine learning, the score indicates whether an infectious pathogen is present in the saliva sample. In certain aspects, the methods and systems operate to determine if an individual is infected with COVID-19 based on Raman spectrum data of a saliva sample of the individual.

9.WO/2021/233769A SLEEP-BASED BIOMETRIC TO PREDICT AND TRACK VIRAL INFECTION PHASES
WO 25.11.2021
Int.Class G16H 50/20
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
20for computer-aided diagnosis, e.g. based on medical expert systems
Appl.No PCT/EP2021/062798 Applicant KONINKLIJKE PHILIPS N.V. Inventor GARCIA MOLINA, Gary, Nelson
An apparatus and method involve leveraging unobtrusive sleep monitoring technologies, even consumer ones, to predict the phase of a viral infection and is usable for guiding patient treatment and tracking treatment effectiveness. An apparatus and method determine a phase of a viral infection based at least in part upon a data set that is input to an algorithm.
10.3836159AN AUTOMATED, CLOUD-BASED, POINT-OF-CARE (POC) PATHOGEN AND ANTIBODY ARRAY DETECTION SYSTEM
EP 16.06.2021
Int.Class G16H 50/80
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
80for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
Appl.No 20211392 Applicant AUTONOMOUS MEDICAL DEVICES INC Inventor SHACHAR JOSH
The present invention relates to an automated cloud-based system for diagnostically field testing a sample taken from a subject using an automated portable handheld instrument to determine the presence of viral antigens and/or antibodies thereto.According to the present invention, the system comprises a reader for automatically processing the sample using the instrument, and a detector for automatically detecting a quantitative measure of the viral antigens and/or antibodies in the sample using the corresponding means of detection in the portable handheld instrument.The system further comprises a data output circuit for automatically generating the detected quantitative measure of the viral antigens and/or antibodies, and a communication circuit for automatically communicating the data output to a cloud-based database.The system also comprises a cloud-based ecosystem for comparatively analyzing the communicated data output relative to a plurality of different types of viral antigens and/or antibodies to diagnose the type of viral infection, if any, the subject most likely carries or has previously carried, and for automatically communicating the results of the comparative analysis to the subject from the cloud-based ecosystem.